Combination products have revolutionized healthcare by integrating drugs, medical devices, and biologics into single therapeutic or diagnostic tools. While these products offer immense potential to enhance patient outcomes, their regulatory journey is complex and varies across different regions. Understanding the unique regulatory landscape is essential for drug developers seeking clearance or approval in the United States, where guidance is ever-evolving. At the same time, manufacturers in Europe face different regulatory requirements, particularly under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).
Navigating these processes successfully requires careful planning, a deep understanding of standards, and strategic engagement with regulatory bodies. This article explores the intricacies of drug approval processes in the U.S. and Europe, offering insights into overcoming challenges and ensuring a successful submission.
What is a Combination Product?
A combination product is a therapeutic or diagnostic solution integrating two or more regulated components. Combination products can be physically or chemically integrated into a single entity or packaged separately but intended for use together—for instance, a drug packaged with a syringe or an inhaler paired with a biologic formulation. Components of combination products can include:
- Drug/Device: For example, an insulin pen that delivers precise doses of medication.
- Biologic/Device: Such as a vaccine delivered via a pre-filled syringe.
- Drug/Biologic: A treatment combining a therapeutic drug and a biologic component like an antibody.
- Drug/Device/Biologic: Products that incorporate all three elements, such as a biodegradable drug-eluting stent with a biologic coating to reduce the chance of inflammation or rejection.
U.S. Regulatory Landscape
The U.S. regulatory system is structured to leverage specialized expertise for different product categories. The FDA assigns combination products to one of its regulatory centers based on the product’s Primary Mode of Action (PMOA)—the most significant therapeutic effect.
- The Center for Drug Evaluation and Research (CDER) typically oversees products whose primary action is a drug, such as a drug-coated stent combination.
- The Center for Devices and Radiological Health (CDRH) handles cases where the device component is primary, such as a drug-delivery inhaler.
- The Center for Biologics Evaluation and Research (CBER) manages products with a dominant biologic component, such as a monoclonal antibody in a pre-filled syringe.
- Complex assignments: In cases where the PMOA is ambiguous (e.g., drug-biologic combinations), the Office of Combination Products determines the lead center, ensuring coordinated oversight across relevant regulatory teams.
For drug developers aiming to bring combination products to the U.S. market, mastering the intricacies of the American regulatory framework is non-negotiable. The structured yet rigorous pathways ensure product safety and efficacy, but navigating these processes effectively requires early preparation and informed strategy.
The Office of Combination Products (OCP) was established to streamline the regulatory oversight of combination products, recognizing the unique challenges posed by their complexity. It ensures that these products are appropriately classified and reviewed by the correct regulatory center while promoting consistency and efficiency. The OCP also serves as a key facilitator between the different regulatory centers, ensuring a coordinated and timely review of combination products.
OCP’s responsibilities include:
- Classification: Determining whether a product is a drug, device, biologic, or combination product.
- Assignment: Allocating the regulatory center for premarket review and post-market safety.
- Guidance: Providing regulations, standard operating procedures, and training for industry stakeholders.
- Dispute resolution: Addressing challenges in timeliness or jurisdictional conflicts during the review process.
- Post-market safety: Overseeing the ongoing safety of combination products on the market.
The OCP plays a vital role in helping developers navigate the complex regulatory landscape of combination products by ensuring regulatory clarity and facilitating collaboration across the agency’s three centers.
Leveraging the Q-Submission Process
Early interaction with U.S. regulatory authorities is essential to streamline the approval process for combination products. The Q-Submission (Q-Sub) program provides several pathways for manufacturers to engage regulators:
- Pre-Submissions (Pre-Subs): Allow manufacturers to seek feedback on planned studies, improving submission quality and potentially reducing review times.
- Study Risk Determinations: Help sponsors and investigators assess whether a device study is significant risk (SR) or non-significant risk (NSR).
- Informational meetings: Facilitate discussions to familiarize regulators with new technologies or devices before formal submissions.
These early dialogues clarify expectations and build collaborative relationships with regulatory bodies, which can be crucial for complex combination products. A qualified testing lab partner could be a valuable resource while preparing for these meetings and supporter while meetings are taking place, providing valuable input and perspective throughout the regulatory process.
Europe: Notified Bodies and Structured Dialogue
In Europe, combination products are reviewed under the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). Unlike in the U.S., where the FDA centralizes regulatory oversight, the EU relies on Notified Bodies (NBs)—independent organizations designated by EU member states—to assess and certify compliance with regulatory requirements.
Recently, efforts have been made to improve communication between manufacturers and NBs. The MDCG 2022-14 guidance encourages NBs to engage in Structured Dialogue with manufacturers before and during conformity assessment. The goal is to enhance the efficiency and predictability of regulatory approval while maintaining compliance with the MDR/IVDR.
NBs can discuss areas such as project plans, submission requirements, requirements for reporting change, use of guidance and standards, and costs or timelines. However, NBs cannot complete gap analyses, check for MDR/IVDR readiness, review mock files for MDR/IVDR conformity, provide technical solutions, or explain how the manufacturer should meet specific regulatory requirements.
While Structured Dialogue offers a way to address regulatory uncertainties, the scope remains limited, leaving many manufacturers uncertain about compliance expectations until late in the process.
Testing Standards and Guidelines
Combination products must meet stringent testing standards to ensure safety and efficacy. Two primary frameworks guide extractables and leachables testing for these products: USP and ISO.
United States Pharmacopeia (USP): A set of public quality standards that ensure the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements. USP standards like USP <1663> and USP <1664> provide guidance for assessing extractables and leachables in pharmaceutical packaging and delivery systems. These chapters outline best practices for designing extraction studies, selecting solvents, and using analytical techniques.
International Organization for Standardization (ISO): A global body that develops and publishes international standards. ISO 10993-18 focuses on the chemical characterization of medical device materials, ensuring their safety and compatibility with human use.
To create a comprehensive test plan for combination products, both USP and ISO standards must be carefully harmonized. In Europe, manufacturers must also consider MDR/IVDR requirements, which emphasize biocompatibility, material safety, and clinical evidence. Similar to navigating meetings with regulatory bodies, a testing lab with experience in combination products can be essential for developers who lack this knowledge.
Common Regulatory Questions and Challenges
Combination product manufacturers often face complex questions from regulators during the submission process. Preparing clear, scientifically supported answers is crucial to avoiding delays and building regulatory confidence. Common question themes and challenges manufacturers should anticipate include:
- Extraction conditions: Ensuring solvents, temperature, and duration parameters accurately simulate real-world use without introducing artifacts.
- Method qualifications: Validating analytical methods for accuracy, precision, and sensitivity.
- Regulatory feedback loops: Iterative feedback cycles can significantly extend timelines if initial submissions or responses to questions lack critical data.
- Resource constraints: Smaller teams may struggle to align their testing capabilities with stringent regulatory expectations.
- Harmonization of standards: Reconciling diverse testing requirements (e.g., USP vs. ISO) can create conflicts or gaps in testing strategies.
Thorough preparation and anticipation of these questions and challenges can expedite the submission process. Engaging with internal experts, external consultants, and regulatory authorities early on can help mitigate these risks and streamline regulatory timelines.
A Final Word on the Regulatory Processes for Combination Products
Navigating the regulatory path for combination products is complex but achievable with the right strategies. Manufacturers should begin by identifying the PMOA early to streamline regulatory assignments. Early engagement with regulatory authorities—whether through the Q-Submission program in the U.S. or Structured Dialogue with Notified Bodies—can help align expectations and clarify requirements. Testing must be aligned with relevant standards (e.g., USP, ISO, MDR/IVDR), and regulatory inquiries should be anticipated to avoid bottlenecks during review.
For manufacturers in Europe, engaging with Notified Bodies early in the development process can be invaluable. While NBs cannot provide direct consultation, leveraging Structured Dialogue can help clarify submission requirements, expected documentation, and conformity assessment pathways. Additionally, staying informed about evolving MDR/IVDR interpretations and best practice guidance documents can improve preparedness and reduce approval delays.
Collaboration with experts is also essential, as engaging internal teams, external consultants, and regulatory authorities can help refine study designs and address challenges effectively. Throughout the process, manufacturers should ask themselves key questions such as: “Have we identified the most significant therapeutic effect of the product to determine the PMOA?” “Are our testing methods validated to meet regulatory expectations?” and “Have we accounted for cross-center coordination if our product spans multiple categories?”
Manufacturers can confidently guide their products through regulatory waters by combining these strategies with thorough preparation, flexibility, and collaboration. The result is safe and effective products that meet regulatory expectations and transform patient care.
